CD274 and neoplasm: A high mutation rate related to NSCLC suggests that NSCLC cells may have a promising durability of response to immune checkpoint inhibitors (Borghaei et al. 2015; Gettinger et al. 2016; Owonikoko et al. 2021), although an association is lacking between tumour response and PD-L1 expression in the phase 1 trial of atezolizumab (Hellmann et al. 2020).